human lung epithelial carcinoma a549 cell line  (ATCC)

Journal: Cancer & Metabolism

Article Title: Transcriptome-driven constraint-based modelling reveals metabolic targets for ovarian cancer

doi: 10.1186/s40170-026-00425-6

Figure Lengend Snippet: TPI1 knockdown reduces colony formation ability and cell proliferation of OV56 and A549. ( A ) Representative immunoblot for TPI1 in the OV56 cell line. Non-targeting siRNA (NTsiRNA) lysate has been titrated to allow an approximate estimate of the TPI1 protein expression in the siTPI1 sample. ( B ) Exemplar colony formation assay for the OV56 cell line transfected with siRNA (NTsiRNA, siTPI1 or siMYC) or exposed to negative control conditions (untreated or transfection reagent only). ( C ) Quantification of colony formation assays. * p < 0.05. Bars indicate standard error. Values have been normalised to NTsiRNA. Three biological replicates represented by data point shapes. ( D ) Exemplar colony formation assay for the A549 cell line transfected with siRNAs as in B. ( E ) Quantification of the colony formation assays. * p < 0.05. Bars indicate standard error. Values have been normalised to NTsiRNA. Three biological replicates represented by data point shapes. ( F ) Proliferation effect of siTPI1 (OV56 and A549 cell lines) (calculated as doubling time before/after siRNA transfection) compared with NTsiRNA calculated as a ratio of the normalised phase object count at time point 100 h for the siTPI1 compared with the NTsiRNA conditions. Biological replicates and mean proliferation effect have been plotted. ( G ) Representative plot for the proliferation of OV56 cells upon siRNA transfection (NTsiRNA: black, siTPI1: pink, siMYC: teal). Live cell microscopy assay, using the Incucyte S3 ® live-cell analysis system (Sartorius). Biological repeats for this experiment have been shown in Supplementary Fig. . ( H ) Representative plot for the proliferation of A549 cells upon siRNA transfection. Live cell microscopy assay, using the Incucyte S3 ® live-cell analysis system (Sartorius). Biological repeats for this experiment have been shown in Supplementary Fig.

Article Snippet: The A549 human lung carcinoma cell line (ATCC, Cat#CCL-185; RRID: CVCL_0023) and OV56 serous adenocarcinoma (Sigma Aldrich, Cat# 96020759; RRID: CVCL_2673) cell lines were cultured in their optimal media conditions, in a humidified environment with 5% CO 2 , at 37 °C.

Techniques: Knockdown, Western Blot, Expressing, Colony Assay, Transfection, Negative Control, Microscopy, Cell Analysis

Journal: Die Naturwissenschaften

Article Title: In vitro antiproliferative activity on A549 and HT-29 cell lines and fatty acid profiling of Agaricus bresadolanus and A. hortensis

doi: 10.1007/s00114-026-02089-0

Figure Lengend Snippet: The antiproliferative activity of the extract of A. bresadolanus on A549 lung cancer cells. Data points represent mean inhibition percentages. Error bars represent mean ± SD from three independent experiments. ( p < 0.01)

Article Snippet: The human lung carcinoma epithelial cell line A549 (ATCC, CCL-185TM), human colorectal adenocarcinoma cell line HT-29 (ATCC, HTB-38TM) and NIH/3T3 fibroblast (ATCC, CRL-1658TM) used in the current work were commercially available.

Techniques: Activity Assay, Inhibition

Journal: Die Naturwissenschaften

Article Title: In vitro antiproliferative activity on A549 and HT-29 cell lines and fatty acid profiling of Agaricus bresadolanus and A. hortensis

doi: 10.1007/s00114-026-02089-0

Figure Lengend Snippet: The antiproliferative activity of the extract of A. hortensis on A549 lung cancer cells. Data points represent mean inhibition percentages. The results given as mean ± SD from three independent experiments. ( p < 0.01)

Article Snippet: The human lung carcinoma epithelial cell line A549 (ATCC, CCL-185TM), human colorectal adenocarcinoma cell line HT-29 (ATCC, HTB-38TM) and NIH/3T3 fibroblast (ATCC, CRL-1658TM) used in the current work were commercially available.

Techniques: Activity Assay, Inhibition

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet: (a) Cell viability assay in cells treated or not for 72 hours with increasing concentrations of pladienolide B (nM). Mean ± SD. n = 3. (b) Quantification of apoptosis (%) by flow cytometry in cells treated with 5 nM pladienolide B for indicated times. Mean ± SD. n = 3. (c) Clonogenic assay in H460S/R cells treated or not for 14 days with 1 nM pladienolide B or 1 µM cisplatin. Lower panel: number of colonies with number in untreated condition being arbitrarily assigned to 100% survival. Mean ± SD. n = 3. (d) Spheroids from H460S/R cells treated with complete medium and DMSO as control, or 0.5 nM or 1 nM pladienolide B for the indicated days. Upper panels: representative images of spheroids at day 14. Lower panel: spheroids area (µm 2 ). Mean ± SD. n = 5 spheroids/condition. A representative experiment of 3 independent ones. (e) Representative immunoblots of SF3B1 in H460S/R or A549S/R cells. GAPDH was used as a loading control. n = 3. (f) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. Left panels: representative immunoblots of SF3B1. GAPDH was used as a loading control. Right panels: quantification of apoptosis (%). Mean ± SD. n = 3. (a, b, c, d, f) Unpaired t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001, ns: not significant. (g) Overall Rate Response (ORR) at Day 20 for all NSCLC PDXs treated or not (control) with 2.5 mg/kg or 5 mg/kg pladienolide B (ip, Day 1-Day 4-Day 8-Day 11). Two-tails Mann-Whitney t test. ** p< 0.01. (h) Probability of progression (Relative Tumor Volume = 2) in control and pladienolide B-treated PDXs. n = 7 (LCIM1 is not included). Log-rank t test. ** p < 0.01.

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: Viability Assay, Flow Cytometry, Clonogenic Assay, Control, Western Blot, Transfection, MANN-WHITNEY

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet:

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: Inhibition, Mutagenesis

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet: (a, b) H460R or A549R cells were transfected for 72 hours with a control siRNA or two distinct siRNA targeting Sf3b1 mRNA as indicated. (a) Left panels: representative immunoblots of the indicated proteins. GAPDH was used as a loading control. Right panels: densitometric quantification (fold change) of SF3B1, ATR or DNA-PKcs signal normalized to GAPDH signal. Mean ± SD. n=3. (b) RT-qPCR (fold change) of SF3B1 , ATR or PRKDC mRNA level. Mean ± SD. n = 3. (a, b) Mann-Whitney t test. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p<0.0001. (c) Correlation between SF3B1 and DNA-PKcs or ATR protein levels in a series of 77 NSCLC cell lines based on CCLE database. (d) Correlation between SF3B1 and PRKDC mRNA levels in lung adenocarcinoma patients retrieved from TCGA public database.

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: Transfection, Control, Western Blot, Quantitative RT-PCR, MANN-WHITNEY

Journal: bioRxiv

Article Title: The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

doi: 10.64898/2026.02.17.706284

Figure Lengend Snippet: (a) Overall Rate Response (ORR) of all NSCLC PDXs (n = 25) treated with 4 mg/kg cisplatin, 5 mg/kg pladienolide B or a combination of both as compared to vehicle condition. Two-tails Mann-Whitney t test. ** p< 0.01, *** p< 0.001. (b) Probability of tumor progression (Relative Tumor Volume = 2) in control, pladienolide B-, cisplatin- or pladienolide B + cisplatin-treated PDXs. n = 7. Log-rank test. * p< 0.05, ** p < 0.01, *** p< 0.001. (c) LCF26 and ML1LC2 PDXs were treated with vehicle (ctrl), 4 mg/kg cisplatin, 5 mg/kg pladienolide B, or a combination of both. Left panels: immunoblots of DNA-PKCs and ATR. 3 PDXs/condition. GAPDH was used as a loading control. Right panels: normalized expression of DNA-PKcs or ATR according to GAPDH. Mann-Whitney t test. * p< 0.05, ** p< 0.01. (d) RT-PCR analysis of skipping of MLH3 -Ex8 in each PDX (3 distinct mice/PDX). Representative agarose gels of amplified products. Right numbers indicate amplicon size (in base pairs). Below numbers indicated the percentage of exon 8 exclusion. Mean ± SD.

Article Snippet: Human Non-Small Cell Lung Carcinoma (NSCLC) cell lines (H460, A549, H1299, H2170, H3255, H460, PC9, CALU-1, H1975, H226, H358, HCC827) were authenticated by DNA STR profiling (ATCC cell line Authentification Service, LGC standards, Molsheim, France) and routinely tested for mycoplasma contamination.

Techniques: MANN-WHITNEY, Control, Western Blot, Expressing, Reverse Transcription Polymerase Chain Reaction, Amplification

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Phage isolation and functional characterization reveal strong antibiofilm activity against Pseudomonas aeruginosa in a cystic fibrosis sputum model

doi: 10.3389/fcimb.2026.1753740

Figure Lengend Snippet: Phage pretreatment inhibits P. aeruginosa PAO1 colonization of human lung epithelial cells. A549 cell monolayers were pretreated with phage PA-319 (10 9 PFU/mL) for 30 minutes, as described in the Materials and Methods section, and subsequently infected with P. aeruginosa PAO1 (10 6 CFU/mL) for 6 hours. (A) Quantification of planktonic and cell-associated (attached and intracellular) bacteria by CFU enumeration. Data represents the mean ± SD of three experiments in eight technical replicates. Statistical significance was determined using unpaired t -tests between control and treatment groups (* p < 0.05, **p < 0.01, ***p < 0.001 ). (B) SEM of PAO1 colonization on untreated A549 cells (three representative images from the control group). (C) SEM of PAO1 colonization on A549 cells pretreated with phage PA-319 (three representative images from the phage-treated group). Bacterial microaggregates in the colonization sites are indicated by red arrows.

Article Snippet: The human lung carcinoma cell line A549 (CCL-185; ATCC) was cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) and maintained in 75 cm 2 flasks at 37 °C.

Techniques: Infection, Bacteria, Control